Endocrine properties assessment of Chemicals, ingredients, & Products

LABORATO RE WATCHFREG





Gregory LEMKINE Scientific Director & CEO www.watchfrog.fr






Regulatory context on endocrine disruptors

European Parliement adopted WHO definition:

An exogenous substance or mixture that **alters function(s)** of **the endocrine system** and consequently causes **adverse health effects** in an intact organism, or its progeny, or (sub)populations (WHO/IPCS 2002).



WATCHFR®G

OECD Guidance Doc 150 investigation levels

LEVEL 1

EXISTING DATA
AND NON-TEST
INFORMATION

LEVEL 2

"IN VITRO"
ASSAYS
Toviding data o

providing data on endocrine mechanisms/ pathways.

LEVEL 3

"IN VIVO" ASSAYS

providing data about selected endocrine mechanisms / pathways. Some assays may also provide some evidence of adverse effects

LEVEL 4

"IN VIVO" ASSAYS

providing data on adverse effects on endocrine relevant endpoints

LEVEL 5

"IN VIVO" ASSAYS

providing more comprehensive data on adverse effects on endocrine relevant endpoints over extensive parts of the life cycle of the organism.

Cosmetic Compliant


Weight of evidence



An endocrine system in vitro

To test endocrine activity of ingredients, it requires a physiological *in vitro* solution:


- ✓ On early stages just hatched larvae
- = **alternative method** to Replace (3Rs) laboratory animals Compliant with European, Swiss and UK Ethical Rules
- ✓ On Whole organisms
 - = Robust results





Fluorescence reveals physiological pathway


Hormone/ Chemical








Range of tests





Medaka eggs




ChgH:

- Constituent protein of the egg envelope.
- Production induced by oestrogens.


WATCHFREG

Rapid Estrogen ACTivity *In Vivo* REACTIV assay





Concentration - Response with an estrogen





Testing strategies







- Chemicals, Ingredients (natural extract) vs Formula
- Packaging influence, food contact
- Hazard based: cover EATS modes of action
- Potency is useful in predictive / screening approach



Dr. Gregory LEMKINE

Scientific Director & CEO

@: lemkine@watchfrog.fr



Tèl: +33 (0)1 69 36 11 15 • Mail: info@watchfrog.fr